August Troendle Sells 650 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 650 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the transaction, the chief executive officer directly owned 539,894 shares in the company, valued at $334,880,051.38. This trade represents a 0.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Medpace Price Performance

MEDP opened at $583.21 on Wednesday. The company has a market cap of $16.28 billion, a price-to-earnings ratio of 34.19, a price-to-earnings-growth ratio of 2.65 and a beta of 1.15. The firm has a 50 day simple moving average of $570.29 and a 200 day simple moving average of $496.46. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the business posted $3.10 earnings per share. Medpace’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Royal Bank Of Canada raised their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Robert W. Baird increased their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $584.18.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently made changes to their positions in the company. American Capital Management Inc. acquired a new stake in shares of Medpace during the second quarter worth about $111,329,000. California State Teachers Retirement System grew its position in shares of Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock valued at $12,505,000 after purchasing an additional 4,719 shares during the period. Focus Partners Advisor Solutions LLC acquired a new position in shares of Medpace in the 2nd quarter valued at approximately $1,685,000. BlackRock Inc. bought a new stake in Medpace during the 2nd quarter worth approximately $1,323,047,000. Finally, Local Pensions Partnership Investment Ltd increased its stake in Medpace by 10.5% during the 2nd quarter. Local Pensions Partnership Investment Ltd now owns 42,000 shares of the company’s stock worth $22,265,000 after purchasing an additional 4,000 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.